Numinus' Phase I clinical trial will evaluate safety/tolerance properties of its Psilocybe mushroom product.
Numinus' Phase I clinical trial will evaluate safety/tolerance properties of its Psilocybe mushroom product.
Champignon Brands has had its Cease Trade Order lifted and can resume trading on the CSE effective April 23, 2021 (symbol: SHRM).
MindMed Inc (CAN:MMED / US:MMEDF) has received approval to commence trading on the NASDAQ starting April 27th. Symbol: MNMD.
Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
Cybin adds several experts in mental health to its Clinical Advisory Board.
Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
Mydecine commences screening psilocybin-based drug candidates.
Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now